

REF. No.: LASA/SE/25-26/04

Thursday, April 24, 2025

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
--	--

**Sub: Press Release**

Attached is the copy of Press Release titled **“Lasa Supergenerics Limited Announces the Expansion of Manufacturing Capacity of API Albendazole to meet the Growing Demands”** issued by the Company.

You are requested to note the above on your records.

Thanking You.

Yours faithfully,

**FOR LASA SUPERGENERICS LIMITED**

**MITTI JAIN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO. A33681**



## Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

### **Lasa Supergenerics Ltd Expands Manufacturing Capacity of API Albendazole to meet Global Demand.**

**Mumbai, 24th April, 2025** – *Lasa Supergenerics Ltd*, a leading innovator in the animal and human healthcare value chain, is pleased to announce the successful expansion of its manufacturing capacity for **Albendazole USP**. This enhancement was achieved through strategic debottlenecking of existing infrastructure and the installation of new machinery at its manufacturing facility.

This expansion strengthens Lasa's ability to meet increasing demand for Albendazole across domestic and international markets, reaffirming its position as a trusted supplier of high-quality Active Pharmaceutical Ingredients (APIs). The Expansion will further achieve Increased Capacity of Albendazole USP, Improve Product Efficiency and reduce lead time, enhance global supply capacity with adherence to top-tier quality and standards.

With the said Expansion the Total capacity is anticipated to represent a growth of **20%**.

This expansion is supported by a capital investment (CAPEX) of nearly **Rs. 100.00 Lakhs** which is already deployed and additional will be deployed over the time.

**Dr. Omkar Herlekar, Chairman and Managing Director** of the Company, said, with our vision we are thrilled to announce this significant expansion of our Albendazole USP manufacturing capacity. It underscores our dedication to supporting our customers and fortifying our role as a reliable API supplier in the pharmaceutical industry."

**About Lasa Supergenerics Limited ([www.lasalabs.com](http://www.lasalabs.com) : BSE: 540702; NSE: LASA)**

Founded in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Konkan Region, Maharashtra

**For more details please visit: [www.lasalabs.com](http://www.lasalabs.com)**

**For any Investor Relations query, please contact:**

**Mitti Jain**

**Lasa Supergenerics Limited**

**Email: [compliance@lasalabs.com](mailto:compliance@lasalabs.com)**



## Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

**Note:** *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*













